Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2719744 | The American Journal of Medicine | 2009 | 11 Pages |
Abstract
In this review 4 experts consider the major safety concerns relating to bisphosphonate therapy for osteoporosis. Specific topics covered are skeletal safety (particularly with respect to atypical fractures and delayed healing), gastrointestinal intolerance, hypocalcemia, acute-phase (i.e., postdose) reactions, chronic musculoskeletal pain, renal safety, and cardiovascular safety (specifically, atrial fibrillation).
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Robert R. Recker, E. Michael Lewiecki, Paul D. Miller, James Reiffel,